Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Bendamustine Hydrochloride for Injection, USP, in 25 mg per vial in a single-dose vial and 100 mg per vial in a single-dose vial.
Meitheal will offer Bendamustine Hydrochloride for Injection, USP in a pack of 1 vial for both presentations.
ABOUT BENDAMUSTINE HYDROCHLORIDE FOR INJECTION, USP
Bendamustine Hydrochloride for Injection is an alkylating drug indicated for treatment of patients with:
- Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
- Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- For full prescribing information, and safety information, please click on the following link.
Learn more about Bendamustine Hydrochloride for Injection
